APA (7th ed.) Citation

L, K., I, P., J, V., ET, T., G, B., L, M., . . . K, S. (2024). PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease. Frontiers in immunology, 14, 1326078. https://doi.org/10.3389/fimmu.2023.1326078

Chicago Style (17th ed.) Citation

L, Kocheise, et al. "PD-1/PD-L1 Immune Checkpoint Therapy Demonstrates Favorable Safety Profile in Patients with Autoimmune and Cholestatic Liver Disease." Frontiers in Immunology 14 (2024): 1326078. https://doi.org/10.3389/fimmu.2023.1326078.

MLA (9th ed.) Citation

L, Kocheise, et al. "PD-1/PD-L1 Immune Checkpoint Therapy Demonstrates Favorable Safety Profile in Patients with Autoimmune and Cholestatic Liver Disease." Frontiers in Immunology, vol. 14, 2024, p. 1326078, https://doi.org/10.3389/fimmu.2023.1326078.